Key points are not available for this paper at this time.
The oral dosing regimen selected for subsequent Phase II/III clinical trials on the basis of these results was 200 mg twice daily, equivalent to 3 mg kg-1 twice daily.
Purkins et al. (Mon,) studied this question.